FDA Approves HIV Drug from Pfizer and GlaxoSmithKline Joint Venture (PFE, GSK)

FDA Approves HIV Drug from Pfizer and GlaxoSmithKline Joint Venture (PFE, GSK)

RSS

On Tuesday, the Food and Drug Administration (FDA) approved a new HIV treatment drug from ViiV Healthcare, a joint venture between GlaxoSmithKline plc (GSK) and Pfizer (PFE).

The FDA approved 50-milligram tablets of the drug Tivicay. Tivicay, when combined with other medications, is supposed to help the treatment of HIV-1 in adults and some children.

ViiV Healthcare submitted data to regulators data from four late-stage clinical studies that treated 2,557 adults and some data from tests on children 12 and older.

ViiV Healthcare was created in 2009 by the British-based GlaxoSmithKline and New York-based Pfizer to specialize in HIV treatments.

Pfizer shares were up 10 cents, or 0.34%, during pre-market trading on Tuesday, while GlaxoSmithKline shares were up 38 cents, or 0.74%.

The Bottom Line
Shares of Pfizer (PFE) offer a dividend yield of 3.29% based on last night’s closing price of $29.19 and the company’s annualized dividend payout of 96 cents per share.
Shares of GlaxoSmithKline (GSK) offer a dividend yield of 4.31% based on last night’s closing price of $51.30 and the company’s annualized dividend payout of $2.21 per share.

Pfizer (PFE) is recommended at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from Dividend.com.

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today